Abstract
The present invention provides a method for proliferating neural progenitor cells and a composition for treating neurological diseases, the composition including a proliferated neural progenitor cell. When a fetal neural progenitor cell is cultured under a hypoxia condition and/or in a medium containing tocoperol, tocoperol acetate, or a mixture thereof, the improved cell proliferation rates of the fetal neural progenitor cell are confirmed. In addition, considering an effect of the neural progenitor cell on preventing differentiation thereof into neurons at the time of proliferation, the present disclosure may contribute to mass production of neural stem cells, and accordingly, the proliferated neural progenitor cell is expected to be utilized in the treatment of a neurological disease.
Claims
1. A method for proliferating a stem cell, the method comprising: culturing the stem cell in a medium comprising tocoperol, tocoperol acetate, or a mixture thereof.
2. The method of claim 1, wherein the culturing of the stem cell is performed under a hypoxia condition.
3. The method of claim 1, wherein the stem cell is a neural progenitor cell.
4. The method of claim 1, wherein the stem cell proliferates in an undifferentiated state.
5. The method of claim 1, wherein the medium comprises tocoperol, tocoperol acetate, or a mixture thereof at a concentration in a range of about 0.01 μg/ml to about 10 μg/ml.
6. The method of claim 5, wherein the tocoperol and tocoperol acetate are mixed at a ratio in a range of about 1:5 to about 5:1.
7. The method of claim 1, wherein the medium further comprises basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF).
8. The method of claim 7, wherein the medium further comprises fibroblast growth factor 4 (FGF4).
9. The method of claim 2, wherein the hypoxia condition comprises atmospheric oxygen at a concentration in a range of about 0.1% to about 10%.
10. A method composition for treating a neurological disease, the composition comprising administrating a neural progenitor cell cultured in a medium comprising tocoperol, tocoperol acetate, or a mixture thereof.
11. The method composition of claim 10, wherein the neurological disease is a disease selected from the group consisting of Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple system atrophy, Parkinson's disease dementia, stroke, ischemia, and neurological disease caused by spinal cord injury.
12. A culture medium for proliferating a neural progenitor cell in an undifferentiated state, the culture composition comprising tocoperol, tocoperol acetate, or a mixture thereof.
Description
DESCRIPTION OF THE DRAWINGS
[0022] FIG. 1 shows results obtained by cell viability through an MTT assay after fetal neural progenitor cells were cultured in each medium for 7 days.
[0023] FIG. 2 shows results of microscopic examination (see FIG. 2A) and cytometry (see FIG. 2B), on fetal neural progenitor cells that were cultured in each medium for 7 days.
[0024] FIGS. 3A to 3D each shows comparison of expression rates of Ki67, Ki67+Nestin upon Dapi markers in a medium after the fetal neural progenitor cells were cultured in each medium for 7 days and then subjected to immunostaining.
[0025] FIGS. 4A to 4E each shows results of comparing expression rates of GFAP, Tuj1, GFAP+Tuj1 upon Dapi markers in a medium after the fetus neural progenitor cells were cultured in each medium for 7 days and then subjected to immunostaining.
BEST MODE
[0026] Hereinafter, the present invention will be described more fully with reference to the following examples. However, these examples are for illustrative purposes only, and thus, should not be construed as being limited to the examples set forth herein.
EXAMPLE 1
Measurement of Cell Viability by 3-(4,5-dimethyltiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) Assay
[0027] Human neural progenitor cells were isolated from 14 week-old human fetuses. Before obtaining the fetus samples, informed consents that had been sufficiently described to parents in advance were received. In addition, the sample collection and use thereof for research were approved by the Institutional Review Board of the CHA Hospital. Ventral midbrain tissues in the brain of a 14-week-old human fetus were isolated according to the method disclosed in Storch et al. 2001; and Milosevic et al. 2006, 2007, and then, dissociated into a single cell suspension by treating the ventral midbrain tissues in a solution containing 0.1 mg/ml of papain and 100 μg/ml of DNase at a temperature of 37□ for about 30 minutes. The single cell suspension was washed with phosphate buffered saline (PBS), and then, incubated in 50 μg/ml of antipain at a temperature of 37□ for 30 minutes. The resulting neural progenitor cells were plated, in a monolayer, at a density of 30,000 cells/cm.sup.2, onto a culture dish that was pre-coated with 15 μg/ml of poly-L-ornithine and 4 μg/ml of fibronectin, and then, cultured. The cultured fetus neural progenitor cells were seeded on a 96-well plate at a density of 1×10.sup.4 cells/well, cultured for 7 days, and treated with an MTT reagent. Then, by measuring optical density thereof (at a wavelength of 570 nm), the cell viability was analyzed.
[0028] FIG. 1 shows results obtained by cell viability through an MTT assay after fetal neural progenitor cells were cultured in each medium for 7 days. 20 ng/ml of each of bFGF and EGF (available from Peprotech, R&D system) and 10 ml of a B27 supplement (available from GIBCO) were added to 500 ml of a mixed medium of DMEM/F12 (1:1) containing 0.5 ml of Primocin, which is an antibiotic formulation, and then, the fetal neural progenitor cells were cultured under a condition in which 1 μg/ml of DL-alpha-tocopherol acetate (M3), 1 μg/ml of (±)-alpha-tocopherol (M4), or a combination thereof (M5) was added. The resulting fetal neural progenitor cells were compared with those cultured under a general culture condition. Regarding the general culture condition, 20 ng/ml of each of bFGF and EGF and an α-supplement (2.5 mg insulin, 25 mg transferrin, 0.03 μM sodium selenite, 36.5 mg L-glutamin, and 0.75 g L-glucose) were added to 500 ml of a mixed medium of DMEM/F12 (1:1) containing 0.5 ml of Primocin, which is an antibiotic formulation, and then, the fetal neural progenitor cells were cultured therein (M1), or under a condition in which the B27 supplement was further added (M2).
[0029] As a result, in comparison with the fetal neural progenitor cells cultured under the general culture condition, the medium containing alpha-tocoperol and/or DL-alpha-tocoperol acetate showed higher cell viability that is statistically significant (Ps <0.02). In addition, in comparison with the fetal neural progenitor cells cultured under a normoxia condition, the medium under a hypoxia condition containing atmospheric oxygen in a range of about 0.1% to about 10% showed higher cell viability that is statistically significant (M3: P<0.009, M4: P<0.01, M5: P<0.001).
[0030] Therefore, it was confirmed that the cell viability of the fetus neural progenitor cells increased upon the treatment of DL-alpha-tocoperol acetate and/or alpha-tocoperol, and more particularly, such a synergistic effect was shown under a hypoxia condition.
EXAMPLE 2
Cytometry
[0031] The fetal neural progenitor cells were seeded on a 6-well plate at a density of 2×10.sup.5cells/well, cultured for 7 days, and then subjected to cytometry.
[0032] FIG. 2 shows microscopic examination (see FIG. 2A) and cytometry (see FIG. 2B), on the fetal neural progenitor cells that were cultured in each medium for 7 days. Here, each culture condition from M1 to M5 was the same as described in Example 1. Compared to the fetal neural progenitor cells cultured under a general condition, the significantly increased number of fetal neural progenitor cells was detected when fetal neural progenitor cells were cultured in a medium containing 1 μg/ml of alpha-tocoperol and/or 1 μg/ml of DL-alpha-tocoperol acetate (Ps<0.0001). Under hypoxia, in comparison with a single treatment either DL-alpha-tocoperol acetate or alpha-tocoperol, combinatorial treatment with both DL-alpha-tocoperol acetate and alpha-tocoperol increased the number of fetal neural progenitor cells of significance (M3 vs. M4: P<0.003, M3 vs. M5: P<0.0006). Under a normoxia condition, in comparison with addition of DL-alpha-tocoperol acetate only, treatment of both DL-alpha-tocoperol acetate and alpha-tocoperol showed a statistically significant increase in the number of fetal neural progenitor cells (M3 vs. M5: P<0.009).
[0033] Consequently, the greatest number of fetal neural progenitor cells was confirmed in the experimental groups treated with both DL-alpha-tocoperol acetate and alpha-tocoperol.
EXAMPLE 3
Immunocytochemistry Analysis 1
[0034] The fetal neural progenitor cells were seeded on a 24-well plate at a density of 1×10.sup.5 cells/well, cultured for 7 days, and then, subjected to immunocytochemistry analysis using Ki67, Nestin, and DAPI markers.
[0035] FIGS. 3A to 3D each shows the comparison of expression rates of Ki67, Ki67+Nestin upon Dapi markers in a medium after the fetal neural progenitor cells were cultured in each medium for 7 days and then subjected to immunostaining.
[0036] In FIG. 3B, in comparison with the fetal neural progenitor cells that were cultured in M1 and M2 which represent a general culture condition, the fetal neural progenitor cells that were in M3 with DL-alpha-tocoperol acetate only, M4 with alpha-tocoperol only, or M5 with both DL-alpha-tocoperol acetate and alpha-tocoperol displayed increased expression of Ki67 of significance (Ps<0.0001). Under a hypoxia condition, in comparison with addition of alpha-tocoperol alone, supplement of both DL-alpha-tocoperol acetate and alpha-tocoperol marginally induced more expression of Ki67 (M4 vs. M5: P=0.05). Among the general culture conditions, addition of B27 supplement (M2) showed increased expression of Ki67 in a statistically significant manner, as compared to absence of the B27 supplement (M1) (Ps<0.03).
[0037] In FIG. 3C, in comparison with the fetal neural progenitor cells cultured under the general culture condition, the neural progenitor cells cultured with DL-alpha-tocoperol acetate, alpha-tocoperol, or both DL-alpha-tocoperol acetate and alpha-tocoperol showed higher frequency of expression of both Ki67 and Nestin together in a statistically significant manner (Ps≦0.0001). Among the hypoxia conditions, in comparison with addition of alpha-tocoperol only, supplement of both DL-alpha-tocoperol acetate and alpha-tocoperol led to higher frequency of expression of both Ki67 and Nestin both of significance (M4 vs. M5, P<0.02).
[0038] In FIG. 3D, in comparison with the fetal neural progenitor cells cultured under normoxia, the fetal neural progenitor cells cultured under hypoxia showed increased expression of Dapi (F.sub.4, 48=57.91, P<0.0001). In addition, in comparison with the fetal neural progenitor cells that were cultured under normoxia, the fetal neural progenitor cells cultured with DL-alpha-tocoperol acetate, alpha-tocoperol, or both DL-alpha-tocoperol acetate and alpha-tocoperol showed statistically significant increase in the expression of Dapi (Ps≦0.0001). Among hypoxia conditions, in comparison with the fetal neural progenitor cells cultured with either DL-alpha-tocoperol acetate or alpha-tocoperol alone, the fetal neural progenitor cells cultured with both DL-alpha-tocoperol acetate and alpha-tocoperol showed statistically significant increase in the expression of Dapi (M3 vs. M5, P<0.0001, M4 vs. M5, P<0.0002). Under the conditions in which only alpha-tocoperol was added and both DL-alpha-tocoperol acetate and alpha-tocoperol were added, the fetal neural progenitor cells showed statistically significant increase in the expression of Dapi under such hypoxia conditions as compared with those cultured under a normoxia condition (in comparison with the normoxia condition, M4 and M5 of the hypoxia conditions had P<0.006 and P<0.0001, respectively).
[0039] Therefore, it was confirmed that the experimental groups treated with both DL-alpha-tocoperol acetate and alpha-tocoperol showed higher expression of Dapi, high percentage of cells showing positive Ki67,a proliferation marker, or high percentage of cells showing positive Ki67 and positive Nestin, a neural progenitor cell marker (see FIGS. 3B to 3D).
EXAMPLE 4
Immunocytochemistry Analysis 2
[0040] The neural progenitor cells were seeded on a 24-well plate at a density of 1×10.sup.5 cells/well, cultured for 7 days, and then, subjected to immunocytochemistry analysis using GFAP, Tuj1, and DAPI markers.
[0041] FIGS. 4A to 4E each shows comparison of expression rates of GFAP, Tuj1, GFAP+Tuj1, and Dapi markers in a medium after the fetal neural progenitor cells were cultured in each medium for 7 days and then subjected to immunostaining.
[0042] In FIG. 4B, in comparison with the fetal neural progenitor cells cultured in M1 and M2, which each represent a general culture condition, the fetal neural progenitor cells that were in M3 including DL-alpha-tocoperol acetate only, M4 including alpha-tocoperol only, or M5 including both DL-alpha-tocoperol acetate and alpha-tocoperol showed reduced expression of GFAP in a statistically significant manner (Ps<0.04). In addition, among the general culture conditions, addition of the B27 supplement (M2) reduced expression of GFAP of significance compared to absence of the B27 supplement (M1) (hypoxia condition: P<0.006, general normoxia condition: P<0.007).
[0043] In FIG. 4C, in comparison with the fetal neural progenitor cells cultured in M1 and M2, which each represent a general culture condition, the fetal neural progenitor cells that were in M3 including DL-alpha-tocoperol acetate only, M4 including alpha-tocoperol only, or M5 including both DL-alpha-tocoperol acetate and alpha-tocoperol showed reduced expression of Tuj1 in a statistically significant manner (Ps<0.02). In addition, among the general culture conditions, addition of the B27 supplement (M2) significantly reduced expression of Tuj1, as compared to a case without the B27 supplement (M1) (hypoxia condition: P<0.008).
[0044] In FIG. 4D, in comparison with the fetal neural progenitor cells cultured under the general culture condition, the fetal neural progenitor cells cultured with DL-alpha-tocoperol acetate, alpha-tocoperol, or both DL-alpha-tocoperol acetate and alpha-tocoperol showed lower frequency of expression of both GFAP and Tuj1 together (Ps<0.0001). In addition, among the general culture conditions, addition of the B27 supplement (M2) lowered frequency of expression of both GFAP and Tuj1 together, as compared to a case without the B27 supplement (M1) (hypoxia condition: P<0.003, general normoxia condition: P<0.001).
[0045] In FIG. 4E, in comparison with the fetal neural progenitor cells cultured under the general culture condition, the fetal neural progenitor cells cultured with DL-alpha-tocoperol acetate, alpha-tocoperol, or both DL-alpha-tocoperol acetate and alpha-tocoperol showed statistically significant increase in expression of Dapi (Ps<0.0001). In addition, among the general culture conditions, addition of the B27 supplement (M2) increased expression of Dapi, as compared to absence of B27 supplement (M1) (normoxia condition: Ps<0.008). In comparison with the fetal neural progenitor cells cultured with alpha-tocoperol under normoxia, the fetal neural progenitor cells cultured with alpha-tocoperol under hypoxia showed statistically significant increase in the expression of Dapi (M4: P<0.006).
[0046] Therefore, it was confirmed that addition of DL-alpha-tocoperol acetate, alpha-tocoperol, or both DL-alpha-tocoperol acetate and alpha-tocoperol lowered the positive cells for GFAP, a neuroglia cell marker, and for Tuj1, a neuron marker, and led to higher expression of Dapi, as compared with those found in the cases under the general culture condition.
